E-resources
-
Emery, Caroline M; Hieronymus, Haley; Zhao, Jean J; Boehm, Jesse S; Golub, Todd; Yang, Xiaoping; Root, David E; Roberts, Thomas M; Hahn, William C; Hill, David E; Wilson, Christopher J; Weber, Barbara L; Garraway, Levi A; Johnson, Laura A; Kim, Sungjoon; Harris, Jennifer L; Kim, So Young; Vidal, Marc; Finan, Peter M; Myer, Vic E; Sellers, William R; Barretina, Jordi; Alkan, Ozan; Thomas, Sapana R; Wardwell, Leslie; Cogdill, Alexandria P; Dummer, Reinhard; Schlegel, Robert; Stransky, Nicolas; Flaherty, Keith T; Wargo, Jennifer A; Murray, Ryan R; Johannessen, Cory M; Salehi-Ashtiani, Kourosh; Caponigro, Giordano
Nature, 12/2010, Volume: 468, Issue: 7326Journal Article
Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.